FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer

Dionysios Papadatos-Pastos, Kiruthikah Thillai, Roy Rabbie, Paul Ross, Debashis Sarker

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)


Treatment of metastatic and locally advanced pancreatic cancer has made slow progress during the last decade. Single agent gemcitabine or in combination with capecitabine or erlotinib remained the preferred systemic treatment options until 2010 when the ACCORD study demonstrated significantly improved outcomes achieved with FOFIRINOX compared with gemcitabine monotherapy. Since 2010, use of FOLFIRINOX has increased both in metastatic and locally advanced cancer. Despite its gaining popularity among oncologists, unanswered questions remain. Do the often necessary dose modifications affect its efficacy? Are the toxicities manageable and how applicable are the results of the ACCORD study in the general population of patients with newly diagnosed pancreatic cancer? In the present manuscript, we review the published literature regarding the use of FOLFIRINOX, the challenges associated with its use and how it will be optimally incorporated into the management of patients with different stages of pancreatic cancer and ultimately, in a more biomarker-driven pathway algorithm.

Original languageEnglish
Pages (from-to)1115-1125
Number of pages11
Issue number10
Publication statusPublished - Oct 2014


Dive into the research topics of 'FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer'. Together they form a unique fingerprint.

Cite this